Mutual Medical Ohio is from Ohio the oldest and largest health insurance company with over 1.5 million lives covered and is positioning itself as a local industry leader in developing up-to-date policy guidelines for safe and effective medical technologies. For more information visit: https://www.medmutual.com/.
This follows similar coverage decisions made by Highmark and Health Care Service Corporation (HCSC), major licensees of Blue Cross and Blue Shield Association. Aetna and Humana also cover the Breathing Valve System under applicable policies.
“This decision by Medical Mutual will provide expanded access to this critical therapy which dramatically reduces pulmonary hyperinflation associated with severe emphysema, and is sustainable over time,” said Dr. Jason stienecker, division chief for pulmonology at the health system of Lima Memorial in Lima, Ohio. “Respiratory valve therapy can lead to really significant improvements in patients who achieve long-lasting clinical outcomes such as improvements in lung function and quality of life. “
Suction valve system
- Supported by positive clinical, safety and efficacy data from EMPROVEI and REACHI clinical trials and reported by leading US and global researchers.
- Designated as a breakthrough device by the FDA that has demonstrated statistically significant and clinically significant improvements in lung function, reduction in shortness of breath, and improvement in quality of life compared to standard medical care.I
- Designated as the standard care option for patients with severe emphysema according to the 2021 report of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), which gives its highest “A” evidence rating for bronchoscopic lung volume reduction (BLVR) using endobronchial valves. According to the report, this evaluation of the evidence is based on the results of randomized clinical trials with data from multiple clinical trials involving a substantial number of patients, including those treated with the breathing valve system.iii
During the minimally invasive BLVR procedure with the breathing valve, umbrella-shaped endobronchial valves are positioned in selected airways. The valves allow air to flow in only one direction, preventing air from flowing into the diseased part of the lung and redirecting the air to healthier lung tissue. Treatment relieves hyperinflation of diseased parts of the lungs and allows healthier parts of the lungs to expand and function more efficiently. With better breathing, patients suffer less shortness of breath and have improved lung function and, as a result, may be able to do more in their daily life and enjoy a better quality of life.
Patient selection is a critical first step in determining who is eligible for this treatment. A decade of clinical studies has shown that patient selection is one of the most important factors in predicting a positive response to BLVR.i, iv, v To determine if a patient is eligible for respiratory valve therapy, doctors use a completely non-invasive patient screening tool called SeleCT.® and computed tomography (CT) of the patient. This selection method, using criteria validated in the EMPROVE trial, does not require more invasive patient selection methods.I
For more information on Olympus Spiration Valve System offerings, visit these dedicated websites:
Olympus is passionate about the solutions it creates for the medicine, life sciences and industrial equipment industries.
Olympus’ medical business uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve outcomes clinics, reduce overall costs and improve the quality of life for patients. Olympus’ medical portfolio includes endoscopes, laparoscopes and video imaging systems, as well as surgical energy devices, system integration solutions, medical services and a wide range of endotherapy instruments. . For more information, visit www.medical.olympusamerica.com.
I Criner GJ, Delage A, Voelker K, et al. “Improving Lung Function in Severe Heterogeneous Emphysema with the Spiration® Valve System (EMPROVE): a multicenter, open, randomized, controlled trial.” American Journal of Respiratory and Critical Care Medicine. 2019; 200 (11): 1354-1362, 2019.
I Wang G, Li S, Wang C, et. Al. The REACH study, a randomized controlled trial evaluating the safety and efficacy of endobronchial treatment of the Spiration Valve System for severe emphysema: 12-month follow-up results. European Respiratory Journal. 2017; 50 (61); DOI: 10.1183 / 1393003.congress-2017.OA1465
iii Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD Report 2020. Retrieved from: https://goldcopd.org/gold-reports/. Accessed November 12, 2019.
iv Schuhmann M, Raffy P, Yi Y, et al. CT predictors of response to pulmonary endobronchial valve reduction therapy: comparison with Chartis. American Journal of Respiratory and Critical Care Medicine. 2015; 191 (7): 767-774. doi: 10.1164 / rccm.201407-1205OC.
v Herth FJF, Slebos DJ, Criner GJ, et al. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation – 2019 Update. Breathing. 2019; 97 (6): 548-557.
SOURCE Olympus Medical Systems Group